Jason B. Litten

Jason B Litten MD is the Chief Medical Officer at Chimeric Therapeutics. Jason is an expert in cell therapy and clinical oncology with experience developing some of the first CAR T, TCR and NK cell clinical programs. Jason also has experience leading the clinical and preclinical development of numerous therapeutic monoclonal antibodies and orally available cancer medicines.

Jason joined Chimeric after serving as the Chief Medical Officer at Artiva Biotherapeutics where led built and led Artiva’s clinical and regulatory functions. During his time at Artiva, Jason contributed to launching two clinical NK cell therapy programs, raising over $200 million in private financing and
establishing two foundational corporate partnerships.

Prior to Artiva, Jason was the Vice President of Clinical Development overseeing Solid Tumor Programs at Juno Therapeutics. Before Juno, he was Vice President of Clinical Development at Clovis Oncology. Jason started his industry career in Oncology Clinical Development at Amgen Inc.

Jason holds a BS from Cornell University and MD from Emory University. After medical school, he completed a Residency in General Pediatrics at University of Miami and a Clinical Fellowship in Pediatric Hematology & Oncology at UT Southwestern. Since leaving academic medicine almost 15 years ago, Dr Litten has been dedicated to developing new medicines for cancer patients in the biotech and pharmaceutical field.